RAPP
Rapport Therapeutics, Inc.
30.90$
-0.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +32.7% | +67.8% | -4.3% | -4.9% | -4.1% | -5.5% | +87.5% | -4.3% | -2.9% | -7.8% | |
| – | – | +31.7% | +71.4% | -4.3% | -5.0% | -6.1% | -7.1% | +92.7% | -4.2% | -2.8% | -7.8% | |
| – | – | +5.8% | +48.3% | -64.3% | +44.5% | +1.4% | -4.4% | +356.5% | -79.1% | +48.3% | -18.5% | |
| – | – | +31.0% | +73.9% | -4.6% | -4.8% | -6.5% | -8.7% | +97.0% | -4.4% | -2.8% | -8.5% | |
| – | – | – | – | – | – | – | – | – | – | – | +405.2% | |
| – | – | +35.8% | -96.3% | -12.8% | +18.4% | +70.6% | +35.6% | +7.8% | +17.2% | -6.1% | +38.2% | |
| – | – | +12.3% | -18.1% | -12.3% | +23.5% | +7.0% | +26.6% | +20.5% | +33.1% | -6.0% | +58.8% | |
| – | – | +2.4% | +2.5% | +2.4% | +2.4% | +36.8% | +74.5% | +41.1% | +11.0% | -5.1% | -5.4% | |
| – | – | -42.1% | +29.5% | -29.4% | +47.7% | +9.5% | +48.5% | +1.9% | +29.5% | +56.6% | -57.4% | |
| – | – | – | – | -4.1% | -5.5% | -6.4% | -7.8% | +94.2% | -5.3% | -2.7% | -10.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -5.3% | +7.6% | +3.4% | -4.7% | +0.6% | +0.0% | +83.8% | +7.0% | +23.9% | +0.6% | +0.5% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.